Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
, Encourages Investors with Losses to Contact Firm - EconoTimes)
NEW YORK, Sept. 29, 2016 -- Scott + Scott, Attorneys at Law, LLP, a global shareholder rights litigation firm, has opened an investigation on behalf of investors in Zosano Pharma Corp (ZSAN). The investigation focuses on whether Zosano and certain of its executives and directors made false statements to investors about the Company’s osteoporosis drug program, ZP-PTH, and its collaboration agreement with Eli Lily and Company.
Investors who own Zosano stock are encouraged to contact Scott + Scott at (646)-582-0121 or email [email protected] to discuss their legal rights.
Scott + Scott, LLP is investigating potential violations of the federal securities laws in connection with the Company’s January 27, 2015 Initial Public Offering (“IPO”). In particular, the firm is investigating whether Zosano and certain of its executives and directors made false statements and omitted material information about the Company’s osteoporosis drug program, ZP-PTH, and its collaboration agreement with Eli Lily and Company.
What You Can Do
If you purchased shares of Zosano, you may have legal claims against the Company. If you wish to discuss the investigation, or have questions about your legal rights, please contact Joseph Halloran, Esq. by telephone at (646)-582-0121 or by email at [email protected].
About Scott + Scott, Attorneys at Law, LLP
Scott + Scott, Attorneys at Law, LLP has significant experience prosecuting major securities, antitrust, and employee retirement plan actions throughout the United States. The firm has offices in New York, London, Connecticut, California and Ohio. Please visit www.scott-scott.com for more information about the firm.
Contact Scott + Scott, Attorneys at Law, LLP Joseph Halloran 646.582.0121 [email protected]
